Sign in or Register   Sign in or Register
  |  

Mouse Anti-CFB Recombinant Antibody (10B2566) (CBMAB-C2195-LY)

This product is antibody recognizes CFB. The antibody 10B2566 immunoassay techniques such as: ELISA, FC, IHC-F, WB.
See all CFB antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
10B2566
Antibody Isotype
IgG1
Application
ELISA, FC, IHC-F, WB

Basic Information

Immunogen
Human factor B
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Preservative
0.09% sodium azide
Concentration
1 mg/ml
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Complement Factor B
Introduction
This gene encodes complement factor B, a component of the alternative pathway of complement activation. Factor B circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the catalytic subunit Bb. The active subunit Bb is a serine protease which associates with C3b to form the alternative pathway C3 convertase. Bb is involved in the proliferation of preactivated B lymphocytes, while Ba inhibits their proliferation. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6. This cluster includes several genes involved in regulation of the immune reaction. Polymorphisms in this gene are associated with a reduced risk of age-related macular degeneration. The polyadenylation site of this gene is 421 bp from the 5' end of the gene for complement component 2. [provided by RefSeq, Jul 2008]
Entrez Gene ID
629
UniProt ID
P00751
Alternative Names
Complement Factor B; B-Factor, Properdin; Properdin Factor B; C3/C5 Convertase; EC 3.4.21.47; PBF2; BFD; GBG; BF; Glycine-Rich Beta-Glycoprotein; Glycine-Rich Beta Glycoprotein;
Function
Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.
Biological Process
Complement activation Source: Reactome
Complement activation, alternative pathway Source: Reactome
Regulation of complement activation Source: Reactome
Cellular Location
Secreted
Involvement in disease
Macular degeneration, age-related, 14 (ARMD14): Disease susceptibility may be associated with variants affecting the gene represented in this entry. Haplotype analyses have identified a statistically significant common risk haplotype and two protective haplotypes. CFB variant His-9 and C2 variant Asp-318, as well as CFB variant Gln-32 and a variant in intron 10 of C2, confer a significantly reduced risk of AMD. A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Hemolytic uremic syndrome atypical 4 (AHUS4): Disease susceptibility is associated with variants affecting the gene represented in this entry. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Complement factor B deficiency (CFBD): An immunologic disorder characterized by increased susceptibility to bacterial infections, particularly Neisseria infections, due to a defect in the alternative complement pathway.

Lee, M. J., Na, K., Shin, H., Kim, C. Y., Cho, J. Y., Kang, C. M., ... & Paik, Y. K. (2021). Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role. Journal of proteome research, 20(12), 5315-5328.

Lu, Q., Hou, Q., Cao, K., Sun, X., Liang, Y., Gu, M., ... & Dai, C. (2021). Complement factor B in high glucose–induced podocyte injury and diabetic kidney disease. JCI insight, 6(19).

Shimazaki, R., Takano, S., Satoh, M., Takada, M., Miyahara, Y., Sasaki, K., ... & Ohtsuka, M. (2021). Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cellular Oncology, 1-14.

Wang, X., Shang, Q. L., Ma, J. X., Liu, S. X., Wang, C. X., & Ma, C. (2020). Complement factor b knockdown by short hairpin rna inhibits laser-induced choroidal neovascularization in rats. International journal of ophthalmology, 13(3), 382.

Pilotti, C., Greenwood, J., & Moss, S. E. (2020). Functional Evaluation of AMD-Associated Risk Variants of Complement Factor B. Investigative ophthalmology & visual science, 61(5), 19-19.

Chen, H., Sun, J., Zhou, B., Peng, J., Xie, Q., Liang, X., ... & Jiang, J. (2020). A missense variant in complement factor B (CFB) is a potential predictor of 24‐week off‐treatment response to PegIFNα therapy in Chinese HBeAg‐positive chronic hepatitis B patients. Alimentary pharmacology & therapeutics, 51(4), 469-478.

Kim, S. H., Lee, M. J., Hwang, H. K., Lee, S. H., Kim, H., Paik, Y. K., & Kang, C. M. (2019). Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Cancer Biomarkers, 24(3), 335-342.

Matsunaga, H., Iwashita, M., Shinjo, T., Yamashita, A., Tsuruta, M., Nagasaka, S., ... & Nishimura, F. (2018). Adipose tissue complement factor B promotes adipocyte maturation. Biochemical and biophysical research communications, 495(1), 740-748.

Coan, P. M., Barrier, M., Alfazema, N., Carter, R. N., Marion de Procé, S., Dopico, X. C., ... & Aitman, T. J. (2017). Complement factor B is a determinant of both metabolic and cardiovascular features of metabolic syndrome. Hypertension, 70(3), 624-633.

Riihilä, P., Nissinen, L., Farshchian, M., Kallajoki, M., Kivisaari, A., Meri, S., ... & Kähäri, V. M. (2017). Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. The American journal of pathology, 187(5), 1186-1197.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CFB Recombinant Antibody (10B2566)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare